Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024

BUY
$0.65 - $1.25 $47 - $91
73 New
73 $0
Q3 2022

Nov 04, 2022

SELL
$1.7 - $20.52 $5,071 - $61,211
-2,983 Reduced 52.46%
2,703 $4,000
Q2 2022

Aug 03, 2022

BUY
$1.35 - $2.29 $7,676 - $13,020
5,686 New
5,686 $11,000
Q1 2022

May 02, 2022

SELL
$1.46 - $2.45 $4,229 - $7,097
-2,897 Closed
0 $0
Q4 2021

Feb 23, 2022

SELL
$2.13 - $3.46 $31,300 - $50,844
-14,695 Reduced 83.53%
2,897 $6,000
Q3 2021

Oct 28, 2021

BUY
$3.14 - $3.9 $628 - $780
200 Added 1.15%
17,592 $67,000
Q2 2021

Aug 12, 2021

SELL
$3.8 - $4.56 $16,780 - $20,136
-4,416 Reduced 20.25%
17,392 $67,000
Q1 2021

Apr 26, 2021

BUY
$4.33 - $6.63 $90,696 - $138,871
20,946 Added 2429.93%
21,808 $100,000
Q4 2020

Feb 02, 2021

BUY
$4.87 - $17.29 $4,197 - $14,903
862 New
862 $5,000
Q4 2019

Feb 05, 2020

SELL
$8.36 - $23.81 $7,716 - $21,976
-923 Closed
0 $0
Q3 2019

Oct 15, 2019

SELL
$9.83 - $14.82 $10,183 - $15,353
-1,036 Reduced 52.88%
923 $9,000
Q2 2019

Jul 26, 2019

BUY
$12.9 - $20.8 $20,098 - $32,406
1,558 Added 388.53%
1,959 $26,000
Q1 2019

Apr 18, 2019

BUY
$17.7 - $24.93 $5,823 - $8,201
329 Added 456.94%
401 $0
Q4 2018

Jan 16, 2019

SELL
$19.05 - $36.45 $55,892 - $106,944
-2,934 Reduced 97.6%
72 $1,000
Q3 2018

Oct 23, 2018

BUY
$34.41 - $44.23 $3,131 - $4,024
91 Added 3.12%
3,006 $111,000
Q2 2018

Jul 30, 2018

BUY
$39.21 - $50.29 $56,109 - $71,964
1,431 Added 96.43%
2,915 $114,000
Q1 2018

Apr 26, 2018

SELL
$41.7 - $64.16 $452,862 - $696,777
-10,860 Reduced 87.98%
1,484 $72,000
Q4 2017

Jan 10, 2018

BUY
$28.58 - $49.91 $147,301 - $257,236
5,154 Added 71.68%
12,344 $558,000
Q3 2017

Oct 25, 2017

BUY
$23.08 - $34.92 $165,945 - $251,074
7,190
7,190 $251,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $717M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.